Male and female patients aged 18 years and older who gave written informed consent to participate in the study with Parkinson's disease, parkinsonism syndrome, were observed for 30 days. Patients of the main group received the drug "Pramipexol BIO" tablets of 0.25 mg. The drug was prescribed together with Madopar. Patients of the comparison group received Madopar for 30 days. The drug Pramipexole BIO 0.25 mg tablets in complex treatment with levodopa significantly expands the possibilities of anti-Parkinsonian therapy both in the early and late stages of PD and SP.
Vitrum cardio Omega-3 a preparation for preventive maintenance thromboprophilia infringements at pregnancy. Hodzhimuratova G. А.
Включение в схемы профилактики и комплексного лечения беременных с тромбофилиями лекарственного препарата Витрум кардио Омега—3 (полиненасыщенная жирная кислота) способствует снижению ингибирования агрегации тромбоцитов,
снижению артериального давления у беременной, предотвращает угрозу преждевременных родов.
The resume: Inclusion in schemes of preventive maintenance and complex treatment of pregnant women with thrombophilia medicai product Vitrum cardio Omega-3 (polynonsaturated fat acid) promotes decrease in inhibition of aggregation trombocits, to decrease in arterial pressure at the pregnant woman, prevents threat of premature birth
A pre-clinical study of the general toxicity of the medication “Fitin-S” has shown that it is referred to class IV of low toxic compounds. The medication “Fitin-S” does not have aaccumulative and local irritant action. At multiple intramuscular administration to rats and rabbits it does not influence the behavior and the dynamics of animals growth, does not cause a toxic effect on the composition of peripheral blood, kidneys’ and liver’s function as well as on the pathomorphology of animals organs and tissues. There is a slowdown in the process of blood coagulation in rabbits at doses of 16 and 32 mg/kg during the whole study period. In 1 month of a recovery period all the indicators have been changing within physiological norm. All the aforementioned data allows us to make a conclusion that the medication does not cause a toxic effect on the organism of animals.
This article describes the results of pathological examinations in experimental tuberculosis using the drug "Rifizostrept"
This article describes the pathomorphological results of testing the drug rifizostrept in guinea pigs.